Marker Therapeutics, Inc. (MRKR) Stock Forecast
MRKR analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $7.87 average of analyst targets
- Upside to target
- +656.4% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.12
- 52-week range
- $0.86 – $2.19
MRKR analyst ratings
3 analystsNumber of analysts at each rating.
MRKR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MRKR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.16 | −$0.12 | −$0.12 | −16.7% | 2 |
| Current fiscal year (2026) | −$0.56 | −$0.63 | −$0.50 | −$0.76 | +26.1% | 2 |
| Next fiscal year (2027) | −$0.53 | −$0.89 | −$0.17 | −$0.56 | +6.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MRKR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.1M | $700,000 | $4.2M | +71.6% | 3 |
| Current fiscal year (2026) | $4.2M | $2.8M | $5.6M | +19.6% | 3 |
| Next fiscal year (2027) | $20.2M | $4.7M | $32.9M | +375.9% | 3 |
MRKR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MRKR revenue: reported and forecast
MRKR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.12 | −$0.18 | −$0.18 | −$0.14 | +16.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.55 | −$0.55 | −$0.69 | −$0.69 | −$0.56 | +2.7% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.17 | −$0.17 | −$0.76 | −$0.76 | −$0.53 | +211.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MRKR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MRKR beat in 8 of 11.
What analysts expect from MRKR
3 analysts cover Marker Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.87, 656.4% above the latest close of $1.04. Analysts expect earnings of −$0.56 per share for 2026, +26.1% from a year earlier. For 2027 the average estimate is −$0.53 per share on revenue of $20.2 million. Marker Therapeutics beat the EPS estimate in 8 of the last 11 quarters.
Related: MRKR income statement, MRKR key metrics, MRKR chart. See the MRKR stock overview for the latest quote and news.
MRKR forecast FAQ
What is Marker Therapeutics's price target?
The average analyst price target for Marker Therapeutics is $7.87, 656.4% above the latest close of $1.04.
Is Marker Therapeutics a buy, hold or sell?
Of 3 analysts covering Marker Therapeutics, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Marker Therapeutics's EPS forecast?
Analysts forecast −$0.56 per share for 2026 (range −$0.63 to −$0.50); for 2027 the estimate is −$0.53.
What is Marker Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $4.2 million, growth of 19.6%; for 2027 it is $20.2 million.
When does Marker Therapeutics report earnings?
Marker Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.12.
Does Marker Therapeutics usually beat earnings estimates?
Marker Therapeutics reported EPS at or above the analyst estimate in 8 of the last 11 quarters.